Skip to Content

  • Search

View Additional Section Content

SWOG S0600 - Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second Line therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX (Accrual suspended 6/6/08).

Clinical Trial Categories

  • Colorectal Cancer
Contact
The Rosenfeld Cancer Center at 215-481-2402

Location

  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details